Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MRNA vs GILD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GILD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

GILD Overall Winner 6-Pillar Tally: MRNA 1 – 5 GILD Matrix Metrics: MRNA 1 – 9 GILD

As of Nov 20, 2026, Gilead Sciences Inc (GILD) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas GILD carries 42.9/100 (HOLD) at $166.43 (16.4x Forward P/E, 38.2% operating margin).

  • Growth vs. Quality Trade-Off: GILD earns the overall head-to-head edge with a stronger Unified Composite Score (42.9/100 HOLD vs. MRNA 40.3/100 SELL) and 0.31β · 30% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs GILD
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89
GILD NASDAQ Head-to-Head Winner
Gilead Sciences Inc
Biological Products, (No Disgnostic Substances)
$166.43
-0.06% 1D
Market Cap $206.6B
TTM Revenue $31.0B
Forward P/E 16.4x
Beta / 30D Vol 0.31β · 30% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 32.0 Fund 49.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.7% over 20 days), RSI 54
RSI-14: 54.5 · SMA20: $167.29 · SMA50: $157.26

6-Pillar Scorecard Institutional Category Breakdown (MRNA 1 – 5 GILD)

Columns: Metric · MRNA · GILD
1. Valuation Multiples GILD
Forward P/E 23.0x 16.4x
Trailing P/E 23.0x 16.8x
PEG Ratio N/M 2.27x
EV / Revenue 33.1x 7.3x
2. Growth & Scale GILD
Revenue Growth (YoY) +29.2% +6.8%
Earnings Growth (YoY) -85.1% -20.2%
TTM Revenue (USD) $2.52B $31.0B
Market Cap $80.7B $206.6B
3. Profitability & Quality GILD
Gross Margin -42.0% 79.9%
Operating Margin -80.8% 38.2%
Net Profit Margin -110.5% -12.5%
Return on Equity (ROE) -34.5% -22.4%
4. Balance Sheet & Cash Flow GILD
Cash Generation (TTM) -$2.04B $13.8B
Cash Flow Margin -81.0% 44.5%
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $19.8B Net Debt (2.01x D/E)
Dividend Yield None (0.00%) 1.92%
5. Options & Positioning GILD
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 89.6% (52nd %ile) 170.9% (61st %ile)
Put/Call OI Skew 1.05x (Balanced) 0.52x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) 41.7% of Rev ($12.9B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (1) vs GILD (9)
Institutional Metric MRNA GILD Criterion Row Edge
Market Capitalization
Scale
$80.7B $206.6B Larger Scale GILD
Trailing P/E Ratio
Valuation
23.0x 16.8x Lower Multiple GILD
Forward P/E Ratio
Valuation
23.0x 16.4x Lower Multiple GILD
Revenue Growth (YoY)
Growth
+29.2% +6.8% Higher Growth MRNA
Operating Margin (TTM)
Profitability
-80.8% 38.2% Higher Margin GILD
Net Profit Margin
Profitability
-110.5% -12.5% Higher Margin GILD
Return on Equity (ROE)
Capital Efficiency
-34.5% -22.4% Higher ROE GILD
52-Week Range Position
Momentum
67% ($22–$281) 83% ($117–$177) Stronger Trend GILD
Beta / 30D Volatility
Risk Regime
2.23β · 78% Vol 0.31β · 30% Vol Lower Realized Risk GILD
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 42.9 / 100 (HOLD) Higher Composite GILD
Trailing 12M Revenue (USD)
Operating Scale
$2.52B $31.0B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% 79.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 33.1x EV/Rev 2.27x PEG · 7.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) $13.8B ($19.8B Net Debt (2.01x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GILD +9.65 pp
MRNA: -3.77% · GILD: +5.88%
3M Horizon MRNA +26.98 pp
MRNA: +40.4% · GILD: +13.42%
6M Horizon MRNA +292.09 pp
MRNA: +315.96% · GILD: +23.87%
1Y Horizon MRNA +676.5 pp
MRNA: +706.45% · GILD: +29.95%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MRNA Revenue GILD Revenue MRNA Op. Margin GILD Op. Margin Margin Leader
FY2018 $140M $22.1B -306.0% 37.1% GILD
FY2019 $60M $22.4B -906.8% 19.1% GILD
FY2020 $800M $24.7B -95.0% 16.5% GILD
FY2021 $18.5B $27.3B 72.0% 36.3% MRNA
FY2022 $19.3B $27.3B 48.9% 26.9% MRNA
FY2023 $6.85B $27.1B -61.9% 28.0% GILD
FY2024 $3.24B $28.8B -121.9% 5.8% GILD
FY2025 $1.94B $29.4B -158.1% 34.0% GILD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GILD SURGE
12d in phase · OBV DISTRIBUTION
Current IV 170.9%
IV Percentile 61st %ile
Put/Call OI Skew 0.52x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GILD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA vs. GILD: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of MRNA ($21,527) vs. GILD ($16,758) against risk-defined 5-day vertical and put-wall option structures.

MRNA Spot $215.27 · IV 83.7%
MRNA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
GILD Spot $167.58 · IV 33.3%
GILD Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $170 / $180 Bull Call Spread

Buy 1x $170C · Sell 1x $180C · 31d

Net Entry $334 Debit
T+5d @ +5% Move +$214 (+64%)
Max Risk / Buffer $334 Capped
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $155 / $145 Bull Put Spread

Sell 1x $155P · Buy 1x $145P · 31d

Net Entry $145 Credit
Max Credit / Yield +$145 (+17.0% RoM)
Max Risk / Buffer -8.4% Cushion ($855 Mgn)
5d Edge & Liquidity 80% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
GILD Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $206.6B market capitalization and 38.2% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($12.9B)
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs GILD Key Questions & Quantitative Answers

As of Nov 20, 2026, Gilead Sciences Inc (GILD) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas GILD carries 42.9/100 (HOLD) at $166.43 (16.4x Forward P/E, 38.2% operating margin). Growth vs. Quality Trade-Off: GILD earns the overall head-to-head edge with a stronger Unified Composite Score (42.9/100 HOLD vs. MRNA 40.3/100 SELL) and 0.31β · 30% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

GILD leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with GILD at +6.8% YoY revenue growth and -20.2% YoY earnings growth on $31.0B TTM revenue (79.9% gross margin, 38.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRNA cumulative revenue shifted +1285.7% while GILD shifted +33.0%. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 41.7% of Rev ($12.9B) (0 disclosures) for GILD.

GILD screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas GILD trades at 16.4x Forward P/E, 16.8x Trailing P/E, 2.27x PEG, and 7.3x EV/Revenue (44.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus GILD (-22.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, GILD carries 170.9% implied volatility (61st %ile, Elevated (60th–80th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.31β · 30% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.